

The Neuro4D Conference 2023

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE
DISEASE
DRUG
DISCOVERY

**MONDAY
MAY 15TH**

7:30		
Registration and Joint Breakfast (Please attach posters!)		
8:30		
Opening of the Conference by Andreas Köpke – bioExert		
9:00		
Alzheimer's Disease Progression and Treatment Options	Cellular Dysfunction and Tau Pathology in Alzheimer's Diseases: Mechanisms and Drug Development	Rakez Kayed University of Texas Medical Branch, USA
PANEL 09:30 – 10:30		
AD Disease Mechanism	Reverting Pathological Post-Translational Protein Modification in AD and PD	Steffen Roßner Uni Leipzig, Germany
	Small Molecule Inhibitors of Histone Acetyltransferases CBP and P300 for Treatment of Alzheimer's Disease	Ottavio Arancio Taub Institute NYC, USA
Enabling Technology	Novel Tools for Drug Discovery in Neurodegenerative Diseases	Jacob McPhail Stressmarq, Canada
Panel Q&A of Session Speakers <i>Chair: Rakez Kayed, University of Texas Medical Branch, USA</i>		
10:30 – 11:30		
Coffee Break, Exhibition & Poster Session (All presenters are at their poster for discussion.)		
PANEL 11:30 – 12:30		
AD New Treatment Strategies (preclinical)	A Novel Druggable Target for Alzheimer's Disease: The Oxidized Conformer of Macrophage Migration Inhibitor (MIF)	Andreas Müller-Schiffmann Heinrich Heine University, Germany
Enabling Technology	Effects of Partial Reduction of Amyloid- β Production on Synaptic Function <i>in vitro</i>	Lotta Agholme Collectricon, Sweden
New Treatment Strategies (preclinical)	Misfolded DISC1 Protein Aggregates as a Druggable Disease Mechanism in Schizophrenia	Carsten Korth Heinrich Heine University, Germany
Panel Q&A of Session Speakers <i>Chair: Rakez Kayed, University of Texas Medical Branch, USA</i>		
12:30		
Lunch		

The Neuro4D Conference 2023

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**MONDAY
MAY 15TH**

13:30		
From Disease Insights to Therapeutic Options	A β Oligomer Targeting in Alzheimer Disease	Neil Cashman ProMIS, Canada
PANEL 14:00 – 15:00		
AD Drug Discovery	Amisulpride as a Disease-Modifying Drug for Tauopathies	Josephine Labus MHH, Germany
Disease Models	Phenotypic Screening of Novel Compounds for Behavioral Aggression in Alzheimer's Disease	Irene Morganstern PsychoGenics, USA
Enabling Technology	Multiplexed Pathway Profiling in Complex Disorders of the Brain: Focus on Alzheimers Disease and Schizophrenia	Moritz Rossner Systasy Bioscience, Germany
Panel Q&A of Session Speakers <i>Chair: Neil Cashman, University of British Columbia, Canada</i>		
15:00 – 17:00		
Coffee Break, Exhibition & Poster Session (All presenters are at their poster for discussion. Please vote for the best poster!) One on One Meetings		
PANEL 17:00 – 18:00		
AD Drug Discovery	Disassembly of Toxic Oligomers by Anti-Prionic Drugs: Evidence from Animal Studies and from Patient Derived Material ex vivo	Antje Willuweit PriAvoid, Germany
Disease Model	Inflammation and AD: Preclinical Drug Testing Systems	Tina Löffler QPS, Austria
AD Drug Discovery	ADvantage AD04 [®] – Offering a New Approach for an Effective and Affordable Disease-Modifying AD Therapy	Achim Schneeberger ADvantage Therapeutics, Austria
Panel Q&A of Session Speakers <i>Chair: Neil Cashman, University of British Columbia, Canada</i>		
18:00		
Local micro brewery beer tasting in the foyer		
19:00 – 22:00		
Dinner We will have a seated barbeque dinner, accompanied by fitting local wines! Depending on the weather, we will be on the hotel terrace, or in an adjacent room.		
END OF THE FIRST DAY		

The Neuro4D Conference 2023

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE
DISEASE
DRUG
DISCOVERY

**TUESDAY
MAY 16TH**

7:30		
Joint Breakfast and Poster Session (Please vote for the best poster!)		
8:30		
New late preclinical and early clinical candidates	Late Preclinical / Early Clinical AD Targets Beyond Anti-Amyloid Approaches	Knut Biber Abbvie, Germany
PANEL 9:00 – 10:00		
AD Models for late preclinical validation	New Biomarkers for Investigating Test Items in the Aged Dog AD Model	Joseph Araujo Transpharmation, Canada
AD Biomarker	Protein Misfolding as a Biomarker for Alzheimer's Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis	Klaus Gerwert University of Bochum, Germany
	Oligomers Count!	Oliver Bannach Attyloid, Germany
Panel Q&A of Session Speakers <i>Chair: Knut Biber, Abbvie, Germany</i>		
10:00 – 11:00		
Coffee Break, Exhibition & Poster Session (All presenters are at their poster for discussion. Final chance to vote for the best poster!) Time for One on One Meetings		
PANEL 11:00 – 12:00		
AD Biomarker	Early Diagnosis of Alzheimer's Disease, Based on the Analysis of Nasal Secretion	Mareike Haack Noselab, Germany
	Development of MS-Based Therapy-Response Biomarkers for Alzheimer's Disease	Stefan Lichtenthaler German Center for Neurodegenerative Diseases (DZNE) and TUM, Germany
	Utility of Four Serum Biomarkers for the Diagnosis of Alzheimer's Disease	Carola Schipke Predemtech AG, Germany
Panel Q&A of Session Speakers <i>Chair: Knut Biber, Abbvie & Oliver Peters, Charité</i>		
12:00		
Lunch		

The Neuro4D Conference 2023

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**TUESDAY
MAY 16TH**

13:00		
Clinical Studies in Alzheimer's Diseases	Recent Defeat and New Hopes!	Oliver Peters Charité, Germany
PANEL 13:30 – 14:50		
AD Clinical Trial	Lessons from Gantenerumab Phase III Trials	Martin Traber Roche, Switzerland
Novel AD Treatment Approach	Plasma Exchange with Albumin Replacement for Alzheimer's Disease	Timo Grimmer TUM, Germany
AD Clinical Trial	Phase Ib Results and Phase II Design for PRI-002 in MCI and Mild Alzheimer's Dementia	Dieter Willbold Priavoid, Germany
	Current Directions in the Treatment of Alzheimer's Disease: Results from the Phase III Study CLARITY AD	Lutz Frölich ZI Mannheim, Germany
Panel Q&A of Session Speakers <i>Chair: Oliver Peters, Charité, Germany</i>		
14:50		
Coffee Break (Please collect your posters!)		
15:30		
Panel Discussion: Are the New Treatments Worth their Risks? We will discuss clinical efficacy and the perceived risk-benefit ratio.		
Participants:		
Oliver Peters	Charité, Germany	
Lutz Frölich	ZI Mannheim, Germany	
Neil Cashman	ProMIS, Canada	
<i>Moderator: Andreas Köpke, bioExpert</i>		
16:15		
Price for the Best Poster – <i>Scientific Progress Towards Improving the Life of Patients and their Families – presented at the International Neuro4D Conference 2023</i>		
16:25		
Summary and Wrap-Up of the Conference		
16:30		
END OF THE CONFERENCE AND DEPARTURE		